.jpg)
Project：ZV0203
Indication：Breast Cancer
Target：HER2++
Approach：FIC
Project：ACR246
Indication：Solid Tumors
Target：5T4
Approach：BIC
Project：ADC2204
Indication：Solid Tumors
Target：Nectin-4
Approach：FIC/FIG,Co-development
Project：ADC2202
Indication：Breast Cancer
Target：HER2-low
Approach：FIG (Dual payload)
Project：ADC2192
Indication：Solid Tumors
Target：Trop2
Approach：FIG (Dual payload)
Project：ADC2313
Indication：Solid Tumors
Target：cMet/EGFR
Approach：FIG (Bispecific)
Project：ADC2336
Indication：Ovarian
Target：Undisclosed
Approach：FIC/BIC
Project：ADC2317
Indication：Colorectal Cancer
Target：Undisclosed
Approach：FIC
Project：ADC2403
Indication：Sarcoma，liver cancer
Target：Undisclosed
Approach：FIC
ADC2122（ZV0203）is a FIC pertuzumab ADC in clinical development, which has a pertuzumab/Perjeta biosimilar antibody, a microtubule inhibitor DUO-5 (a Dolastatin 10 derivative), a proteolytically cleavable valine-citruline dipeptide linker, with antibody-to-drug ratio (DAR) of 2. Pertuzumab is different from trastuzumab in that it binds to HER2 domain II, instead of IV for trastuzumab, and block not only homodimerization of HER2 itself, but also HER2 and EGFR, HER2 and HER3, HER2 and HER4 heterodimerization. Currently ADC2122 has completed Phase I dose titration with no DLT (Dose Limiting Toxicity), SAE (Serious Adverse Event) or SUSAR (Suspected Unexpected Serious Adverse Reaction) incidence with significant antitumor effects at both doses of 2.7mg/kg and 3.6mg/kg.
ACR246, a best-in-class and potentially first-to-launch ADC product, targeting 5T4 oncofetal antigen with a proprietary topoisomerase I inhibitor, has been greenlit for clinical trials in China in January 2024, with FIH trials set to launch in the 1st quarter of 2024. ACR246 standing at the forefront of oncological innovation, is designed with a stable and tumor microenvironment (TME)-cleavable linker, and has demonstrated substantial anti-tumor activity, safety, pharmacokinetics, and tolerability in preclinical studies involving rodent and non-human primate models. The specificity of 5T4, predominantly expressed in various solid tumors and minimally in normal adult tissues, underscores ACR246's potential in a broad spectrum of oncological applications, and heralds a new era in precision oncology.
ADC2204 is a new generation Nectin-4 targeting ADC, which is being co-developed in collaboration with Lunan Pharmaceuticals. It has demonstrated superior safety, efficacy and tolerability compared to PADCEV® in a panel of CDX models.
ADC2202 is a dual payload ADC setting up the new criteria of 3rd generation HER2 ADC. It is developed with MuSC™, which contains two types of drugs of different MOA that have synergistic effects in disrupting cell organelle. It is being evaluated preclinically with DS-8201 head-to-head comparison. Initial data has demonstrated potent antitumor effects and a far superior efficacy compared to DS-8201 in several CDX models.
ADC2192 is a Trop2 targeting dual drug ADC developed based on MuSC™ platform, which consists of two types of payloads with different MOA to promote synergistic effects. It is being evaluated preclinically with a marketed and/or more advanced in development candidate head-to-head comparison. Initial data has already shown excellent synergistic effects and superior efficacy compared to the reference in several CDX models.
For more information，please contact us at BD@adcoris.com.cn